Profile: AutoGenomics Inc

AutoGenomics, Inc., a privately held company based in Carlsbad, CA has developed one of the first automated microarray based multiplexing molecular diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious diseases, cancer and pharmacogenetics. With discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the new era of personalized medicine.

Mission

The Company's mission is to empower clinical laboratories with an automated cost effective solution to perform molecular testing that will significantly enhance work flow, cost efficiency, quicker turn-around time and result with enhanced patient care.

Overview

Since the Company's inception in 1999, scientists and engineers at AutoGenomics have endeavored to create automation and technologies that have simplified the complex test processes inherent in genomic and proteomic analysis within a format that is user friendly and increases productivity in the clinical laboratory.

The INFINITI™ system is designed specifically for processing AutoGenomics' unique proprietary BioFilmChip™ microarrays that can be multiplexed and configured with hundreds of biomarkers to assess disease signatures from a single sample specimen.

The INFINITI™ system provides clinical laboratories with unparalleled workflow improvements, cost reductions through labor savings and reduced cost of reportable results.